Bi-Specific Antibodies Therapy Market

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.
Bi-Specific Antibodies Therapy Market aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy. Bi-Specific Antibodies Therapy Market contains market size and forecasts of Bi-Specific Antibodies Therapy in global, including the following market information:
Global Bi-Specific Antibodies Therapy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Bi-Specific Antibodies Therapy market was valued at US$ 3360.6 million in 2022 and is projected to reach US$ 16260 million by 2029, at a CAGR of 25.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.
North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.
We surveyed the Bi-Specific Antibodies Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bi-Specific Antibodies Therapy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Bi-Specific Antibodies Therapy Market Segment Percentages, by Type, 2022 (%)
Fragment-Based Antibodies
IgG-Based Antibodies
Global Bi-Specific Antibodies Therapy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Bi-Specific Antibodies Therapy Market Segment Percentages, by Application, 2022 (%)
Cancer
Haemophilia
Other Non-Cancer Diseases
Global Bi-Specific Antibodies Therapy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Bi-Specific Antibodies Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bi-Specific Antibodies Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Bi-Specific Antibodies Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Bi-Specific Antibodies Therapy, market overview.
Chapter 2: Global Bi-Specific Antibodies Therapy market size in revenue.
Chapter 3: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bi-Specific Antibodies Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.